Pharmacotherapy
Clinician's Perspective: • Tirzepatide is a medication that targets two distinct hormone receptors: the Glucagon-like Peptide-1 (GLP-1) and the Glucose-dependent Insulinotropic Polypeptide (GIP). As a result, the stomach emptying is slowed down and appetite is reduced. • Dose-Dependent Weight Loss: Across clinical trials lasting 72
Bariatric Surgery
Clinician's Perspective: • Hypertension (High Blood Pressure) is often present in persons with obesity. Effective weight management in the form of Bariatric Surgery may lead to improved Blood Pressure control. • In a randomized controlled trial looking into how Roux en Y gastric bypass affects High Blood Pressure management, at
Pharmacotherapy
Clinician's Perspective: • Researchers identified a specific genetic variant in the GLP1R gene (GLP-1 receptor) (the primary cellular docking site for these drugs) that directly influences how much weight a person loses. • Individuals carrying a specific version of this gene (rs10305420) experienced an additional 0.76 kg of
Understanding Obesity
Clinician's Perspective: • Sarcopenic Obesity (SO) is when Sarcopenia (the age-related loss of skeletal muscle mass and strength) and Obesity (excessive accumulation of body fat or adiposity) occur at the same time. • Data indicates that individuals over 60 years of age in the Asia-Pacific region are at
Bariatric Surgery
Clinician's Perspective: • Data indicates that five years after reaching their nadir (lowest weight point), 50.2% of Roux-en-Y gastric bypass patients regain a modest amount of weight, around 15% of the weight they initially lost. • The GLP-1 Deficit: While bariatric surgery successfully restores the postprandial
Bariatric Surgery
Clinician's Perspective: • Dumping Syndrome (DS) manifests in two distinct windows: Early (within 60 minutes) involving rapid fluid shifts and cardiovascular strain, and Late (1–3 hours) characterized by Reactive Postprandial Hypoglycemia (dangerously low blood sugar following a meal). • Surgical Prevalence: While bariatric surgery is highly effective for weight
Understanding Obesity
Clinician's Perspective: • Global Projections: Researchers estimate that by 2030, 60% of the world’s population will be overweight or obese, with obesity currently accounting for 44% of all diabetes cases. • The "diabesity" Phenomenon: The term "diabesity" describes the nearly inseparable relationship between obesity and
Understanding Obesity
Clinician's Perspective: • The true driver of colorectal cancer: body fat distribution. • The Waist-to-Hip Ratio (WHR) (a measure of central obesity) proved to be a significantly more accurate predictor of colorectal cancer than total body weight or BMI. • The "Normal Weight" Illusion: The data revealed
Understanding Obesity
Clinician's Perspective: • Muscle helps improve metabolic health. A 1.9% to 3.3% increase in muscle mass is linked to a 4.1% reduction in fat mass and a 5.8% drop in fasting glucose levels. • With resistance training, the body diverts glucose and amino acids away from
Understanding Obesity
Clinician's Perspective: • Obesity significantly increases the risk of cancer in the gastric cardia (the top part of the stomach where it meets the food pipe), but not in other areas of the stomach. • Individuals classified as obese (a Body Mass Index of 30 or higher) showed a 57%
Understanding Obesity
Clinician's Perspective: • Research involving over 496,000 participants suggests that obesity functions as an important driver of accelerated aging, with nearly 60% of the link between weight and mortality being mediated through age-related cellular diseases. • Telomere Attrition: Obesity is consistently associated with the shortening of Telomeres (the
Lifestyle & Wellness
Clinician's Perspective: • Bidirectional Feedback: The relationship between sleep and weight is a "two-way street" where poor sleep drives weight gain, and excess adiposity (the state of having too much body fat) compromises sleep quality. • Hormonal Dysregulation: Sleep deprivation disrupts the signaling of Leptin (the hormone